Stay updated on Inotuzumab Ozogamicin for B-ALL MRD+ Clinical Trial
Sign up to get notified when there's something new on the Inotuzumab Ozogamicin for B-ALL MRD+ Clinical Trial page.

Latest updates to the Inotuzumab Ozogamicin for B-ALL MRD+ Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check44 days agoChange DetectedThe webpage now includes a notice about heavy traffic affecting NLM-NCBI services and products, along with a contact for assistance. Additionally, a date has been updated from December 10, 2024, to February 6, 2025.SummaryDifference7%
- Check52 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
- Check66 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.3%
- Check73 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference1.0%
- Check102 days agoChange DetectedThe latest addition updates the study on Inotuzumab Ozogamicin for treating B-cell Acute Lymphocytic Leukemia, reflecting a new revision (v2.13.3) dated December 10, 2024, while the previous version (v2.13.2) from September 19, 2024, has been removed.SummaryDifference2%
Stay in the know with updates to Inotuzumab Ozogamicin for B-ALL MRD+ Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Inotuzumab Ozogamicin for B-ALL MRD+ Clinical Trial page.